Registry-listed formulations

Alendronate Sodium · mesh:M0329075

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

7 source entries across 7 studies. This list may not include all unresolved or historical entries.

  • Alendronate Sodium Tablets 70mgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Alendronate Sodium Tablets, 10 mgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Alendronate SodiumRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Alendronate Sodium Tablets, 70 mgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Alendronate Sodium Tablets, 70 mgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Alendronate sodiumRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • alendronate sodium powderRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
90.0%

Based on 13 completed trials

Completion Rate
93%(13/14)
Active Trials
2(11%)
Results Posted
31%(4 trials)
Terminated
1(6%)

Phase Distribution

Not Applicable
1
6%
Phase 2/3
1
6%
Phase 4
4
22%
Phase 1
4
22%
Phase 2
5
28%
Phase 3
3
17%

Phase Distribution

4

Early Stage

6

Mid Stage

7

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
4(22.2%)
Phase 2Efficacy & side effects
5(27.8%)
Phase 2/3Combined phases
1(5.6%)
Phase 3Large-scale testing
3(16.7%)
Phase 4Post-market surveillance
4(22.2%)
N/ANon-phased studies
1(5.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.9%

13 of 14 finished

Non-Completion Rate

7.1%

1 ended early

Currently Active

2

trials recruiting

Total Trials

18

all time

Status Distribution
Active(2)
Completed(13)
Terminated(1)
Other(2)

Detailed Status

Completed13
unknown2
Active, not recruiting1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
2
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (22.2%)
Phase 25 (27.8%)
Phase 2/31 (5.6%)
Phase 33 (16.7%)
Phase 44 (22.2%)
N/A1 (5.6%)

Trials by Status

active_not_recruiting16%
terminated16%
unknown211%
recruiting16%
completed1372%

Recent Activity

2 active trials
Showing 5 of 18
completedphase_4

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

NCT05493761
recruitingphase_2

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

NCT06016634
active_not_recruitingphase_4

Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis

NCT06856369
terminatedphase_2

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695
unknownphase_2

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

NCT05397938
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT05493761Phase 4

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

Completed
NCT06016634Phase 2

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Recruiting
NCT06856369Phase 4

Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis

Active Not Recruiting
NCT00019695Phase 2

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Terminated
NCT05397938Phase 2

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Unknown
NCT00354302Phase 3

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Completed
NCT02795546Phase 4

Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects.

Completed
NCT00996801Phase 2

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

Completed
NCT00004488Phase 2

Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease

Completed
NCT00004489Not Applicable

Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis

Completed
NCT00504166Phase 4

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

Completed
NCT00122356Phase 3

Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment

Completed
NCT01133496Phase 1

Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions

Completed
NCT01012934Phase 1

Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)

Completed
NCT00983996Phase 1

Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)

Completed
NCT00835406Phase 1

Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.

Completed
NCT00051558Phase 3

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Completed
NCT00209469Phase 2/3

Network Osteoporosis Study

Unknown

All 18 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
18